Other
Atypical Endometrial Hyperplasia
10
Pipeline Programs↗
2
Active Trials↗
7
Companies Involved↗
Atypical Endometrial Hyperplasia is an early-stage landscape with 10 programs across 7 companies. The most active players are Bristol-Myers Squibb, Daewon Pharmaceutical Co., Ltd., Bayer. 1 therapy is approved with 4 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 34
Approved1
Analysis
Trial Status
11
clinical trials
Completed5 · 45%
Withdrawn2 · 18%
Recruiting2 · 18%
Terminated1 · 9%
Unknown status1 · 9%
Clinical Trials
Trial Activity
11 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)